Logo do repositório
 
Publicação

Factor XI Inhibitors

2024-03Recensão Acesso aberto
Ver registo simples
dc.contributor.authorPresume, João
dc.contributor.authorFerreira, Jorge
dc.contributor.authorRibeiras, Regina
dc.contributor.institutionComprehensive Health Research Centre (CHRC) - pólo NMS
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblAdis
dc.date.accessioned2024-02-16T01:10:48Z
dc.date.available2024-02-16T01:10:48Z
dc.date.issued2024-03
dc.description.abstractAnticoagulation therapy has undergone significant evolution, marked by the emergence of direct oral anticoagulants with distinct advantages. Despite these advancements, challenges persist in managing residual thrombotic and bleeding risks, particularly among vulnerable populations. The pursuit of alternative drugs has honed in on factor XI/XIa inhibitors. This comprehensive review delves into several key aspects regarding this new target: (i) the role of factor XI in the coagulation cascade; (ii) the genetic evidence and pathophysiologic rationale supporting factor XI inhibition as a therapeutic target; (iii) an exploration of the various types of factor XI/XIa inhibitors currently under investigation; (iv) potential applications of these medications, spanning thromboprophylaxis after orthopedic surgery, stroke prevention in atrial fibrillation, secondary prevention after acute coronary syndrome, non-cardioembolic stroke, thromboprophylaxis after foreign material implantation, end-stage renal disease, and patients with cancer; and (v) an overview of ongoing studies, recent findings, and the future trajectory of research into these drugs.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent448055
dc.identifier.doi10.1007/s40119-024-00352-x
dc.identifier.issn2193-8261
dc.identifier.otherPURE: 82828579
dc.identifier.otherPURE UUID: 3c06e362-0fd8-4186-a1c3-893d540cf189
dc.identifier.otherPubMed: 38306010
dc.identifier.otherScopus: 85184214858
dc.identifier.otherWOS: 001155364900001
dc.identifier.urihttp://hdl.handle.net/10362/163606
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAnticoagulants
dc.subjectAtrial fibrillation
dc.subjectChronic kidney failure
dc.subjectFactor XI
dc.subjectHemorrhage
dc.subjectMyocardial infarction
dc.subjectReview
dc.subjectStroke
dc.subjectVenous thromboembolism
dc.subjectSDG 3 - Good Health and Well-being
dc.titleFactor XI Inhibitorsen
dc.title.subtitleA New Horizon in Anticoagulation Therapyen
dc.typereview
degois.publication.firstPage1
degois.publication.issue1
degois.publication.lastPage16
degois.publication.titleCardiology and therapy
degois.publication.volume13
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
s40119-024-00352-x.pdf
Tamanho:
437.55 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica